PriceTargets.com logo

CRISPR Therapeutics - CRSP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $77.93
  • Forecasted Upside: 91.39%
  • Number of Analysts: 18
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$40.72 As of 12/20/2024 06:51 PM ET
▲ +0.34 (0.84%)

This chart shows the closing price for CRSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CRISPR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRSP

Analyst Price Target is $77.93
▲ +91.39% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for CRISPR Therapeutics in the last 3 months. The average price target is $77.93, with a high forecast of $105.00 and a low forecast of $48.00. The average price target represents a 91.39% upside from the last price of $40.72.

This chart shows the closing price for CRSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 18 contributing investment analysts is to hold stock in CRISPR Therapeutics. This rating has held steady since November 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.00
12/10/2024Chardan CapitalReiterated RatingBuy ➝ Buy$94.00 ➝ $94.00
11/6/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$53.00 ➝ $53.00
11/6/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$59.00 ➝ $55.00
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$84.00 ➝ $84.00
10/4/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$60.00 ➝ $53.00
8/12/2024Truist FinancialLower TargetBuy ➝ Buy$120.00 ➝ $100.00
8/8/2024Cantor FitzgeraldReiterated RatingNeutral
8/6/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$67.00 ➝ $59.00
8/6/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$66.00 ➝ $60.00
8/6/2024Needham & Company LLCLower TargetBuy ➝ Buy$88.00 ➝ $84.00
8/6/2024Chardan CapitalLower TargetBuy ➝ Buy$112.00 ➝ $94.00
8/6/2024Stifel NicolausLower TargetHold ➝ Hold$60.00 ➝ $59.00
8/2/2024Rodman & RenshawInitiated CoverageBuy$90.00
6/28/2024GuggenheimReiterated RatingNeutral
6/27/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$88.00 ➝ $88.00
6/17/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00
6/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$88.00 ➝ $88.00
5/23/2024CitigroupLower TargetBuy ➝ Buy$89.00 ➝ $84.00
5/10/2024OppenheimerLower TargetOutperform ➝ Outperform$102.00 ➝ $95.00
5/9/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$86.00
5/9/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$70.00 ➝ $65.00
5/9/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $67.00
5/9/2024Cantor FitzgeraldReiterated RatingNeutral
5/9/2024Needham & Company LLCLower TargetBuy ➝ Buy$90.00 ➝ $88.00
5/9/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$46.00 ➝ $52.00
4/18/2024CitigroupBoost TargetBuy ➝ Buy$88.00 ➝ $89.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$90.00
3/6/2024MizuhoBoost TargetBuy ➝ Buy$82.00 ➝ $99.00
2/26/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$46.00 ➝ $48.00
2/22/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$57.00 ➝ $66.00
2/22/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$55.00 ➝ $70.00
2/22/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$61.00 ➝ $80.00
2/22/2024Chardan CapitalBoost TargetBuy ➝ Buy$110.00 ➝ $112.00
2/21/2024Needham & Company LLCBoost TargetBuy ➝ Buy$88.00 ➝ $90.00
2/15/2024Wolfe ResearchInitiated CoveragePeer Perform
12/11/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$50.00 ➝ $57.00
12/11/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$56.00 ➝ $61.00
12/11/2023Needham & Company LLCBoost TargetBuy ➝ Buy$85.00 ➝ $88.00
12/11/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $80.00
12/11/2023TD CowenDowngradeMarket Perform ➝ Underperform$30.00
12/8/2023MizuhoReiterated RatingBuy ➝ Buy$82.00
12/8/2023Truist FinancialReiterated RatingBuy ➝ Buy
12/5/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$74.00
11/13/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$43.00 ➝ $42.00
11/7/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$55.00 ➝ $50.00
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$88.00 ➝ $85.00
10/30/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$88.00
10/17/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
9/26/2023MizuhoInitiated CoverageBuy$82.00
8/17/2023CitigroupUpgradeNeutral ➝ Buy$70.00
8/14/2023Morgan StanleyBoost TargetUnderweight ➝ Underweight$42.00 ➝ $43.00
8/10/2023OppenheimerReiterated RatingOutperform ➝ Outperform$102.00
8/8/2023Credit Suisse GroupBoost TargetNeutral ➝ Neutral$62.00 ➝ $63.00
8/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$88.00
8/7/2023Chardan CapitalLower TargetBuy ➝ Buy$123.00 ➝ $110.00
7/25/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$74.00
6/9/2023JMP SecuritiesBoost Target$70.00 ➝ $74.00
6/1/2023BarclaysBoost Target$61.00 ➝ $64.00
5/30/2023William BlairInitiated CoverageOutperform$75.00
5/23/2023CitigroupBoost Target$55.00 ➝ $70.00
5/9/2023VNET GroupReiterated RatingReiterates
5/9/2023Stifel NicolausLower Target$69.00 ➝ $64.00
4/20/2023Needham & Company LLCReiterated RatingBuy$82.00
4/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$75.00
4/17/2023JMP SecuritiesReiterated RatingMarket Outperform$70.00
4/13/2023Cantor FitzgeraldInitiated CoverageOverweight$72.00
4/3/2023EF Hutton Acquisition Co. IReiterated RatingBuy$75.00
3/21/2023Sanford C. BernsteinInitiated CoverageMarket Perform$44.00
3/17/2023CitigroupLower Target$63.00 ➝ $55.00
3/17/2023Bryan, Garnier & CoInitiated CoverageBuy$70.00
3/6/2023Robert W. BairdInitiated CoverageNeutral$46.00
2/27/2023Morgan StanleyBoost TargetUnderweight$37.00 ➝ $39.00
2/27/2023JMP SecuritiesReiterated RatingMarket Outperform$70.00
2/23/2023OppenheimerLower TargetOutperform$110.00 ➝ $102.00
2/22/2023Needham & Company LLCLower TargetBuy$122.00 ➝ $82.00
2/22/2023EF Hutton Acquisition Co. IReiterated RatingBuy$75.00
2/22/2023Credit Suisse GroupLower TargetNeutral$78.00 ➝ $65.00
2/22/2023Chardan CapitalLower TargetBuy$153.00 ➝ $123.00
1/19/2023JMP SecuritiesLower TargetMarket Outperform$100.00 ➝ $70.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$75.00
11/23/2022CitigroupLower TargetNeutral$83.00 ➝ $63.00
11/7/2022Leerink PartnersBoost TargetOutperform$75.00 ➝ $76.00
11/2/2022Royal Bank of CanadaLower TargetSector Perform$79.00 ➝ $70.00
11/2/2022BarclaysLower Target$88.00 ➝ $61.00
11/2/2022Credit Suisse GroupLower Target$90.00 ➝ $78.00
10/11/2022Morgan StanleyInitiated CoverageUnderweight$37.00
8/9/2022Stifel NicolausBoost Target$55.00 ➝ $69.00
8/9/2022Chardan CapitalLower TargetBuy$164.00 ➝ $154.00
8/9/2022Royal Bank of CanadaLower TargetSector Perform$85.00 ➝ $79.00
8/9/2022Credit Suisse GroupBoost TargetNeutral$74.00 ➝ $90.00
8/9/2022BarclaysDowngradeOverweight ➝ Equal Weight$99.00 ➝ $88.00
8/8/2022Leerink PartnersLower TargetOutperform$112.00 ➝ $107.00
8/2/2022CitigroupBoost TargetNeutral$53.00 ➝ $83.00
6/23/2022OppenheimerLower TargetOutperform$150.00 ➝ $122.00
6/22/2022Stifel NicolausReiterated RatingHold$57.00 ➝ $55.00
6/22/2022Chardan CapitalLower TargetBuy$168.00 ➝ $164.00
6/22/2022Piper SandlerBoost TargetOverweight$115.00 ➝ $121.00
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$98.00
6/13/2022Stifel NicolausBoost Target$52.00 ➝ $57.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$52.00 ➝ $46.00
5/23/2022Piper SandlerLower TargetOverweight$180.00 ➝ $115.00
5/17/2022CitigroupLower TargetNeutral$64.00 ➝ $53.00
5/13/2022Needham & Company LLCLower Target$170.00 ➝ $122.00
5/11/2022OppenheimerLower Target$172.00 ➝ $150.00
5/10/2022Royal Bank of CanadaLower Target$95.00 ➝ $85.00
5/10/2022BarclaysLower Target$107.00 ➝ $99.00
5/10/2022Chardan CapitalLower Target$171.00 ➝ $168.00
4/28/2022Credit Suisse GroupInitiated CoverageNeutral$78.00
3/15/2022CitigroupLower TargetNeutral$90.00 ➝ $64.00
2/17/2022The Goldman Sachs GroupLower TargetNeutral$179.00 ➝ $87.00
2/16/2022Stifel NicolausLower Target$64.00
2/16/2022Truist FinancialReiterated RatingBuy$220.00
2/16/2022Royal Bank of CanadaLower TargetSector Perform$117.00 ➝ $95.00
2/16/2022BarclaysLower Target$148.00 ➝ $107.00
2/16/2022Leerink PartnersLower TargetOutperform$126.00 ➝ $120.00
2/14/2022Brookline Capital AcquisitionInitiated CoverageBuy$143.00
2/14/2022Brookline Capital ManagementReiterated RatingBuy$143.00
12/6/2021CowenInitiated CoverageMarket Perform
11/4/2021OppenheimerLower TargetOutperform$185.00 ➝ $172.00
11/4/2021BarclaysLower TargetOverweight$160.00 ➝ $148.00
10/19/2021Leerink PartnersInitiated CoverageOutperform$126.00
10/13/2021Chardan CapitalReiterated RatingBuy$171.00
10/13/2021Stifel NicolausLower TargetHold$139.00 ➝ $101.00
10/13/2021William BlairReiterated RatingBuy
7/30/2021Chardan CapitalLower TargetBuy$175.00 ➝ $171.00
7/7/2021Chardan CapitalReiterated RatingBuy
6/14/2021CitigroupUpgradeSell ➝ Neutral$55.00 ➝ $132.00
5/13/2021Evercore ISIUpgradeOutperform
4/21/2021BarclaysBoost TargetOverweight$140.00 ➝ $160.00
4/21/2021Jefferies Financial GroupUpgradeHold ➝ Buy$172.00
3/4/2021JMP SecuritiesInitiated CoverageOutperform$160.00
3/1/2021BarclaysBoost TargetOverweight$113.00 ➝ $140.00
2/28/2021BarclaysReiterated RatingBuy
2/17/2021The Goldman Sachs GroupLower TargetNeutral$193.00 ➝ $189.00
2/17/2021OppenheimerBoost TargetOutperform$165.00 ➝ $187.00
2/17/2021Chardan CapitalBoost TargetBuy$166.00 ➝ $175.00
2/17/2021Needham & Company LLCReiterated RatingBuy
1/12/2021Truist FinancialBoost Target$170.00 ➝ $210.00
12/10/2020Chardan CapitalBoost TargetBuy$110.00 ➝ $166.00
12/10/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
12/10/2020Needham & Company LLCBoost TargetBuy$105.00 ➝ $170.00
12/10/2020Piper SandlerBoost TargetOverweight$107.00 ➝ $180.00
12/7/2020Stifel NicolausBoost TargetHold ➝ Positive$91.00 ➝ $145.00
12/7/2020OppenheimerBoost TargetOutperform$105.00 ➝ $155.00
12/7/2020Roth CapitalBoost TargetBuy$115.00 ➝ $170.00
12/7/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$102.63 ➝ $145.00
10/30/2020Raymond JamesReiterated RatingSell
10/29/2020Piper SandlerLower TargetOverweight$128.00 ➝ $107.00
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$110.00 ➝ $110.00
10/22/2020Chardan CapitalBoost TargetPositive ➝ Buy$100.00 ➝ $110.00
10/21/2020Stifel NicolausBoost TargetHold$75.00 ➝ $93.00
10/21/2020Roth CapitalBoost TargetBuy$105.00 ➝ $115.00
10/21/2020Piper SandlerBoost TargetOverweight$104.00 ➝ $128.00
10/5/2020Bank of AmericaInitiated CoverageBuy$110.00 ➝ $110.00
8/5/2020CitigroupReiterated RatingSell
7/28/2020Wells Fargo & CompanyBoost TargetOverweight$95.00 ➝ $110.00
7/28/2020Chardan CapitalBoost TargetBuy$72.50 ➝ $100.00
7/28/2020Needham & Company LLCBoost TargetBuy$84.00 ➝ $105.00
7/28/2020William BlairReiterated RatingBuy
7/28/2020BarclaysBoost TargetPositive ➝ Overweight$65.00 ➝ $102.00
7/27/2020OppenheimerInitiated CoverageBuy$89.00 ➝ $105.00
7/14/2020SunTrust BanksInitiated CoverageBuy$140.00
6/23/2020OppenheimerBoost TargetOutperform$80.00 ➝ $89.00
6/19/2020Piper SandlerReiterated RatingOverweight$104.00
6/19/2020Roth CapitalBoost TargetBuy$100.00 ➝ $105.00
6/12/2020Piper SandlerReiterated RatingBuy$104.00
6/12/2020Chardan CapitalReiterated RatingBuy$72.50
6/12/2020Needham & Company LLCInitiated CoverageBuy$84.00
6/12/2020OppenheimerInitiated CoverageBuy$80.00
5/31/2020Chardan CapitalReiterated RatingBuy
5/6/2020Chardan CapitalReiterated RatingBuy
4/29/2020Needham & Company LLCInitiated CoverageBuy$84.00
4/28/2020William BlairReiterated RatingBuy
4/1/2020Piper SandlerReiterated RatingBuy$104.00
3/4/2020Stifel NicolausInitiated CoverageHold$52.00
3/4/2020CitigroupBoost TargetSell$28.00 ➝ $31.00
2/13/2020Piper SandlerReiterated RatingBuy$104.00
2/13/2020Chardan CapitalReiterated RatingBuy$72.50
2/13/2020William BlairReiterated RatingBuy
1/30/2020Chardan CapitalReiterated RatingBuy
12/23/2019Needham & Company LLCReiterated RatingBuy$84.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 23 very positive mentions
  • 32 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 20 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 31 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/24/2024
  • 23 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 20 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 23 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 23 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 23 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More

Today's Range

Now: $40.72
Low: $39.41
High: $41.02

50 Day Range

MA: $48.45
Low: $40.38
High: $55.15

52 Week Range

Now: $40.72
Low: $39.41
High: $91.10

Volume

3,344,844 shs

Average Volume

1,522,809 shs

Market Capitalization

$3.48 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of CRISPR Therapeutics?

The following Wall Street research analysts have issued research reports on CRISPR Therapeutics in the last twelve months: Barclays PLC, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Guggenheim, JMP Securities, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Rodman & Renshaw, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TheStreet, Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for CRSP.

What is the current price target for CRISPR Therapeutics?

0 Wall Street analysts have set twelve-month price targets for CRISPR Therapeutics in the last year. Their average twelve-month price target is $77.93, suggesting a possible upside of 91.4%. Piper Sandler has the highest price target set, predicting CRSP will reach $105.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $48.00 for CRISPR Therapeutics in the next year.
View the latest price targets for CRSP.

What is the current consensus analyst rating for CRISPR Therapeutics?

CRISPR Therapeutics currently has 1 sell rating, 8 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRSP, but not buy more shares or sell existing shares.
View the latest ratings for CRSP.

What other companies compete with CRISPR Therapeutics?

Other companies that are similar to CRISPR Therapeutics include Neurocrine Biosciences, Bio-Techne, Vaxcyte, Qiagen and Exelixis. Learn More about companies similar to CRISPR Therapeutics.

How do I contact CRISPR Therapeutics' investor relations team?

CRISPR Therapeutics' physical mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company's listed phone number is (141) 561-3277 and its investor relations email address is [email protected]. The official website for CRISPR Therapeutics is www.crisprtx.com. Learn More about contacing CRISPR Therapeutics investor relations.